Antibacterial effect of a new phage, MIZ-Pa99, in the treatment of Pseudomonas aeruginosa keratitis in an animal model
- PMID: 40744162
- DOI: 10.1016/j.micpath.2025.107933
Antibacterial effect of a new phage, MIZ-Pa99, in the treatment of Pseudomonas aeruginosa keratitis in an animal model
Abstract
Background: Pseudomonas aeruginosa is one of the common bacterial agents in keratitis and is resistant to drugs. Due to the difference in the mechanism of action of antibacterial compounds, phage therapy can be a therapeutic candidate to deal with drug-resistant infections. The purpose of this study is to isolate, identify, and investigate the antimicrobial ability of a phage sample to treat keratitis caused by P. aeruginosa.
Materials and methods: The Bacteriophage (phage) MIZ-Pa99 isolated from hospital wastewater in Tehran, Iran was identified by TEM imaging. The presence of phage was confirmed by the spot technique and its titration was evaluated using the double-layer agar culture method. Phage lytic activity was evaluated through host range determination against P. aeruginosa, S. aureus, and E. coli, and biofilm destruction assays. Phage's novelty was determined through whole-genome sequencing. Phage safety was assessed using in vitro cytotoxicity assays and in vivo Draize eye irritation tests in rabbit eyes. Therapeutic efficacy was investigated in a mouse model using phage eye drops, with bacterial load quantified by CFU counts and tissue damage assessed by histopathology. Also, the antibiotic resistance pattern of Pseudomonas clinical isolates was investigated.
Results: MIZ-Pa99 belongs to the Straboviridae family and the Caudoviricetes order. Whole genome analysis of MIZ-Pa99 phage showed that it belongs to Elvirus genus, and has linear and double-stranded DNA with a length 209,183 bp and a GC content of 49.30 %. The anti-biofilm effect of phage was observed on clinical isolates. IC50 of phage (HCE-2) was determined as 10-1 dilution (9.93 × 1011 PFU/ml). The synergistic effect of ciprofloxacin and phage in the form of eye drops was observed in the improvement of keratitis caused by P. aeruginosa.
Conclusion: The results obtained in this study indicated that MIZ-Pa99 can be effective in controlling bacterial keratitis infection. However, combined antibiotic and phage treatment has a synergistic effect.
Keywords: Antimicrobial resistance; Bacteriophage; Keratitis; Phage therapy; Pseudomonas aeruginosa.
Copyright © 2025 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Similar articles
-
Efficacy of phage vB_Ps_ZCPS13 in controlling Pan-drug-resistant Pseudomonas aeruginosa from urinary tract infections (UTIs) and eradicating biofilms from urinary catheters.Virol J. 2025 Jul 12;22(1):236. doi: 10.1186/s12985-025-02848-x. Virol J. 2025. PMID: 40652263 Free PMC article.
-
Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates.J Biomed Sci. 2025 Aug 11;32(1):74. doi: 10.1186/s12929-025-01169-z. J Biomed Sci. 2025. PMID: 40790594 Free PMC article.
-
Isolation and characterization of phages ΦZC2 and ΦZC3 against carbapenem-resistant Acinetobacter baumannii, and efficacy of ΦZC3 on A549 cells.Virol J. 2025 Jul 30;22(1):262. doi: 10.1186/s12985-025-02885-6. Virol J. 2025. PMID: 40739242 Free PMC article.
-
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD004197. doi: 10.1002/14651858.CD004197.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Jun 2;6:CD004197. doi: 10.1002/14651858.CD004197.pub6. PMID: 28440853 Free PMC article. Updated.
-
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2017 Apr 25;4:CD004197. doi: 10.1002/14651858.CD004197.pub5. PMID: 25383937 Updated.
LinkOut - more resources
Full Text Sources
Miscellaneous